Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Construction and application of a hunov GII.4 clinical isolate sequence and its infectious clone

An infectious cloning and sequence technology, applied in the fields of biology and genetic engineering, can solve the problem of no HuNoV infectious cloning, etc., and achieve the effect of simple construction method and high reliability

Active Publication Date: 2021-10-08
CHENGDU VIROGEN BIOPHARMACEUTICAL CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Early studies abroad have tried to construct a reverse genetic system of HuNoV, and achieved some success [7, 8], but so far there has been no report of an infectious clone of the Chinese strain of HuNoV

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Construction and application of a hunov GII.4 clinical isolate sequence and its infectious clone
  • Construction and application of a hunov GII.4 clinical isolate sequence and its infectious clone
  • Construction and application of a hunov GII.4 clinical isolate sequence and its infectious clone

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Example 1: Replication and toxin-producing ability of HuNoV infectious clones

[0055] Spread eukaryotic cells A, B, and C on 10 cm cell culture dishes, transfect 10 μg of pCMV-HuNoV plasmid into eukaryotic cells A, B, and C after 16 hours, and collect the cells after 3 days; or spread eukaryotic cells C on a 6-well plate 16 hours later, 3 μg of pCMV-HuNoV plasmid was transfected into eukaryotic cell C, and the cells were collected after 4, 8, 12, 24, and 36 hours of transfection; after centrifugation at 1100pm for 5 minutes:

[0056] Cell pellet:

[0057] 1. Take 107 cells and use the RNA extraction kit from MN Company to extract the total RNA in the cells.

[0058] 2. Using the RNA as a template, use the HuNoV GII nucleic acid detection kit of Sun Yat-Sen University Daan Gene Co., Ltd. to detect the replication of HuNoV RNA in various eukaryotic cells by real-time quantitative PCR (such as figure 2 );

[0059] Cell supernatant:

[0060] 1. Use a 100KD ultrafiltra...

Embodiment 2

[0070] Example 2: Infectivity of Progeny Virions Produced by HuNoV Infectious Clones

[0071] 1. After transfecting C cells with 10 μg pCMV-HuNoV plasmid for 3 days, collect the cell supernatant, centrifuge at 1100 rpm for 5 minutes, pipette the cell supernatant into clean collection tubes, aliquot 1 mL in each tube and store in a -80°C refrigerator for later use.

[0072] 2. Spread 6-well plates with C cells, add 1 mL of virus supernatant to each well after 16 hours and infect for 4 hours, wash with 2 mL of 1×PBS for 3 times, then replace with fresh medium and culture for 24 hours.

[0073] 3. Remove the cell supernatant, add 2mL 1×PBS to each well to wash 3 times, scrape off the cells with a cell scraper, transfer to a 1.5mLEP tube, centrifuge at 1100rpm for 5min, remove the supernatant, and keep the cell pellet.

[0074] 4. Use the RNA extraction kit of MN company to extract the total RNA in the cells.

[0075] 5. Using the RNA as a template, use the HuNoV GII nucleic acid...

Embodiment 3

[0076] Example 3: Infectious replication ability of progeny virions produced by HuNoV infectious clones

[0077] 1. After transfecting C cells with 10 μg pCMV-HuNoV plasmid for 3 days, collect the cell supernatant, centrifuge at 1100 rpm for 5 minutes, pipette the cell supernatant into clean collection tubes, aliquot 1 mL in each tube and store in a -80°C refrigerator for later use.

[0078] 2. Spread 35mm glass-bottomed dishes with C cells, add 1mL virus supernatant to each well after 16 hours and infect for 4 hours, wash with 2mL 1×PBS for 3 times, then replace with fresh medium and culture for 24 hours.

[0079] 3. Remove the cell supernatant, add 2mL 1×PBS to each small dish and wash 3 times.

[0080] 4. Add 1 mL of 4% paraformaldehyde to each well and fix at room temperature for 10 min.

[0081] 5. Remove paraformaldehyde, add 1mL 1×PBS to each small dish and wash once.

[0082] 6. Remove PBS, add 1mL 2% TritonX-100 to each small dish, and permeabilize at room temperatu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a human norovirus (human norovirus, HuNoV) GII.4 Chinese clinical isolate sequence and its infectious clone, as well as the construction method and application of the infectious clone, the clinical isolate sequence and the currently published domestic There are certain differences in the outer HuNoV GII.4 sequence, and the clone can effectively proliferate in a variety of eukaryotic cell lines, and can produce progeny infectious virus particles; the inactivated virus particles can be used as a new type of HuNoV Vaccine development research.

Description

technical field [0001] The invention relates to the fields of genetic engineering and biotechnology. Specifically, the invention relates to the construction and application of a human norovirus (HuNoV) GII.4 Chinese clinical isolate sequence and its infectious clone. The clone is capable of efficiently proliferating in eukaryotic cells and capable of producing infectious progeny virions. Background technique [0002] Human Norovirus (HuNoV) is the main cause of acute non-bacterial epidemic gastroenteritis. It often breaks out in semi-closed communities such as nursing homes, schools, hospitals, cruise ships and disaster relief agencies, and is susceptible to all age groups. Many people, especially infants, the elderly, and immunocompromised individuals [1], still lack NoV vaccines. Once HuNoV breaks out, it is difficult to control. The virus can be spread from person to person through the aerosol-like dispersed virus particles formed by infected person's vomit or feces. Abo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N7/00C12N15/63C12N15/66A61K39/12A61P31/14
CPCA61K39/12A61K2039/5252A61P31/14C12N7/00C12N2770/16021C12N2770/16034
Inventor 胡勤学章牡丹
Owner CHENGDU VIROGEN BIOPHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com